Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Cancer Res Ther ; 19(5): 1103-1108, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37787270

RESUMO

Introduction: In two Korean and Italian studies, the adherence rate (AR) to ASSLD 2005 guidelines in the management of hepatocellular carcinoma (HCC) was 60%. In a US study, the AR to American Association for the Study of Liver Disease (AASLD) 2005 guidelines was 73.3%, 26.8%, 25.3%, and 58.8% for patients with Barcelona Clinic Liver Cancer (BCLC) Stage A, B, C, and D, respectively, and nonadherence to guidelines was associated with longer overall survival (OS) in patients with BCLC Stage D. Here, we explored the AR to AASLD 2018 guidelines and its impact on OS. Methods: Between 2017 and 2019, 148 unique treatment-naïve patients with HCC were identified. Patients were staged according to the BCLC staging system and their AR to AASLD 2018 guidelines was noted. OS was estimated using Kaplan-Meier method. Survivals among patients from different groups was compared using Log-rank test. Results: The overall AR to AASLD 2018 guidelines was 83%. The AR for BCLC Stages 0, A, B, C, and D were 100%, 97%, 77%, 77%, and 38%, respectively. In patients with BCLC Stage D, the OS of patients treated with modalities adherent versus nonadherent to AASLD 2018 guidelines was 0.03 vs. 5.2 months (P = 0.0005). Otherwise, adherence versus nonadherence to AASLD 2018 guidelines showed no statistically significant differences in OS for patients with BCLC Stages 0, A, B, and C. Conclusion: The overall AR to AASLD 2018 guidelines was 83%. Nonadherence to AASLD 2018 guidelines in patients with BCLC Stage D translated into better OS.


Assuntos
Carcinoma Hepatocelular , Neoplasias Hepáticas , Humanos , Carcinoma Hepatocelular/patologia , Neoplasias Hepáticas/patologia , Estadiamento de Neoplasias , Estudos Retrospectivos , Itália , Prognóstico
2.
Cureus ; 14(9): e29324, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-36277592

RESUMO

Single benign or neoplastic dermal lesions are very common. Lesions with two distinct tumors occurring as a single entity are extraordinary and known as collision tumors. In the present case, the lesion was diagnosed on biopsy, and later, wide local skin excision was performed. Excision revealed that the lesion was composed of two distinct cell populations exhibiting the characteristics of two separate neoplastic entities. The histopathology revealed a single lesion comprised of moderately differentiated squamous cell carcinoma that appeared to invade an atypical fibroxanthoma. This is unprecedented in the English literature and the first such case to be reported.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA